{"name":"Gilgamesh Pharmaceuticals","slug":"gilgamesh-pharmaceuticals","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"GM-2505","genericName":"GM-2505","slug":"gm-2505","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"GM-2505","genericName":"GM-2505","slug":"gm-2505","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi_AFBVV95cUxOQ3JLVTk4RzZBTkFVdktSU2d3dkYxeUpfODRQRUdtcDdYUi12YU9LYkZiYUxfRzJkV0d3dllzSFlIbmI3ejZMV05tSll3UVBYbGM1dHhldjc5NVNkMmpEb2kyeE5xTTZpVzVZakZRWjEzQzE5bEw4Q3ktWFlONG9jeTR3MnhOVl9OY2JMdVhHMlZMbXo4NGhCZkEwSGR0UWhvN041VG5FdDFOb04tcmVhMHliUFZaMkctazNVRml2R3RJWndJaWFDOVY5Mzl0Z04ycnFySlpUQXVSbmlibF9QT0xFU0JBM1Btd2FNOUR5TW41cVo2Qi1KczlET1M?oc=5","date":"2026-03-24","type":"pipeline","source":"PR Newswire","summary":"Gilgamesh Pharma Closes Oversubscribed $60 Million Series A to Develop Next Generation Neuropsychiatric Therapies - PR Newswire","headline":"Gilgamesh Pharma Closes Oversubscribed $60 Million Series A to Develop Next Generation Neuropsychiatric Therapies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxOQlJ5S1hGb2NXTzd3akNQYlZEYy13WEdNUGV0NElwTENTOUtYV0Vub1ZKLVlmSkREa0pkcWg5YkdkTENMbkFQTk9wSXhxQzZzVEswV3Bxdzh1ZERkU0g1cTBIQk9zb2pvbmlTUmZsd0JTRzE2OVBOdUpDTXprNllQOHZKa1FIdnJPLWVDdHZkUkI3VXZRR3dXd2Fn?oc=5","date":"2025-09-22","type":"pipeline","source":"BioSpace","summary":"Psychedelics Space Enters New Era as AbbVie Dives In - BioSpace","headline":"Psychedelics Space Enters New Era as AbbVie Dives In","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxPaU5SMmVmWk40bXNCbHFTNl9QUVVGMEtMdW5PcVNwSUp2NVBDLWpIOTd2eHRmOU9uSmpwcDJ1eWhCV1FqclFhM01LWWxJdkl4RGNEQUJGNTBIYTJGN0tDTVFrZmhjM05Xai11ellkMzI1TF9wVnJydUNJSDl3U04zR2JMM2o1Y2VvUXZSZGxaYTZHbVhreUVjR0MyNEgtRG93d2l0a3plY04tMkE?oc=5","date":"2025-08-27","type":"regulatory","source":"CHEManager","summary":"AbbVie to Acquire Gilgamesh Pharmaceutical’s Psychedelic Drug for $1.2B - CHEManager","headline":"AbbVie to Acquire Gilgamesh Pharmaceutical’s Psychedelic Drug for $1.2B","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxNbE1xREZMUjdmZHpzWWlaSm9wZ3ladEtYUTF1a2FveUhCYThpUF9iWkJPVUpZck1PNzRSMjJMYW40OXN2YjFEdC1vUnpmRnBTSm5BYklGM01kZmlFRHg3OGJSVGY1V3NpNFdsa0kxemJMVFM3aTlxbE9DX0h3UFFJSERYUQ?oc=5","date":"2025-08-25","type":"deal","source":"statnews.com","summary":"AbbVie to buy Gilgamesh’s psychedelic drug for up to $1.2 billion - statnews.com","headline":"AbbVie to buy Gilgamesh’s psychedelic drug for up to $1.2 billion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxNclZCb1ZxMWFSR0FJVHloYUNzUDdqOXRNaU5CS0tTT0ZYRS1TYnllOTdSYlBPZFh3SjVvVUhzRTVnNEtoQjJBZVAzRGhYWXJHRmRxdHRHbE5WTEstVThydjBGMzc4ZlpFdEZvaGtKZGVFUm53ZGRHcE1pRnlGWlozUjY2X0VSYTlxYTYzY1NGaExmbzBGT0ZHSFFjY3ZvQzFM?oc=5","date":"2025-08-25","type":"pipeline","source":"BioPharma Dive","summary":"AbbVie wagers more than $1B on Gilgamesh’s psychedelic drug - BioPharma Dive","headline":"AbbVie wagers more than $1B on Gilgamesh’s psychedelic drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxNV0ZmQTF5ZDZsTndUellwWTJVTzJLVnpVYUhrNG5HeG5tQlhBZ01wVWZGMGZrbm8tQ2ZKSFo1T3c4ejlMNVFaMlpENjVFa3dtc3pXV2RsbGxFTmJXZjRfYmpuQm44ZTlEc1AwN3FNcDM1ckYxcHVUeHRlamh0YlFmWkNVa2pVaEEtVjVwVTlKSjN4bG52ZjFTQ09wUDg0aHhBRUJvNWlWYmdZZlVRUUVPd09PZ2xEMFFKVWxCUG1WSG16U2RNWk5DTmRVVUk?oc=5","date":"2025-08-25","type":"deal","source":"reuters.com","summary":"AbbVie targets psychedelic-based depression drug market with $1.2 billion deal - reuters.com","headline":"AbbVie targets psychedelic-based depression drug market with $1.2 billion deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxPYzdpVVJuaDRZOGtSbnVEVEpPdG54dlVmQVd2RnNSR0tDZ1pmTTBsTmpUSFFudzBpM0R5LXBpTTZDSkd0ckthd0NDZ3hzTmw2SHA1RWtmYlVsNmp0SG0wcGo5MTkzdzUyNHUySXpTdkNGcFlGUUNfMXgxV3BUMFU5a1laa2RYNjF1dGJtdnpwNEVxWi1qRzR0dm15SVpKMi1MUFNVSGREZmpoYmVJNGdjNFVyTUdxS3h4YUthMUxRYUNLOXJWd2NKMHExc1JETGc1aXdlekNzOFFnOUV2eEZfNg?oc=5","date":"2025-08-25","type":"pipeline","source":"Pharmaceutical Executive","summary":"AbbVie Expands Psychiatry Drug Pipeline with Acquisition of Gilgamesh Pharmaceuticals’ Bretisilocin for Major Depressive Disorder - Pharmaceutical Executive","headline":"AbbVie Expands Psychiatry Drug Pipeline with Acquisition of Gilgamesh Pharmaceuticals’ Bretisilocin for Major Depressive","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxOZXVqU0t3NUNrZDZzQjJKb1pyUWlVX3lGWWE3ckNmTjVxVWd2Z3R0RDEyUHVfbngwcW5admwwZ2tCeXk3Y0VnQ0NDTW9ZQk8xTW9VbkliQ0JxUUFOaGt6ejhxcUhjM05RNV9SS3NiM3RlTFo0UXAydTRCT3BBdGh2a0dlVmwxOV9WemFmaQ?oc=5","date":"2025-08-25","type":"deal","source":"pharmaphorum","summary":"Rumour partly confirmed as AbbVie acquires Gilgamesh drug - pharmaphorum","headline":"Rumour partly confirmed as AbbVie acquires Gilgamesh drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE9STDhhQXlTcVRtcUo1UkZVU3RIZ09iOXl4TU9wSmlmanMtQmtKdkFSVjRBWGFzeVBOOVFNQnotWjBrV2thQ05ZbS1KU0pocXlBblJR?oc=5","date":"2025-08-25","type":"deal","source":"FirstWord Pharma","summary":"AbbVie strikes $1.2B deal for Gilgamesh's psychedelic depression therapy - FirstWord Pharma","headline":"AbbVie strikes $1.2B deal for Gilgamesh's psychedelic depression therapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAJBVV95cUxOSkhUSUx4R2trT1p3WlFSck91MHZ5RVNXZDR4X2Y3eml4cG5jWEk0UjZqTEVPQy1LcnlISUlwNkNMQkZ4cUtKNTBaSEF6cGZ0ZFN4LUNxbkJVTEtaQlN5ajJ0YWZqakp5NEo0V3NPenphdFBEaTlPTVJFQ2pjVHplaDlmdnlPLUdnaTBHMm9pVWExbDlUNW5yMUdQN0lNUFUtSktDc1pZMmoxdWlMdGJKT19FOXlPakhVMy1VVGZEb3FhQjM5YWQwa3N0a1B5MXRheEZDajFsWGQ1bUtWY1ZGcGoyOEhqQ1ZqemlrcG1ockxtMFZLeFllbGhRQUU0Y282QWxZZ1h4ZjBWa25lNVI3QURycWhSbWszZHlWZlNXMTR0OWJ3T3l4SDNiSWU?oc=5","date":"2025-08-25","type":"deal","source":"PR Newswire","summary":"AbbVie to Acquire Gilgamesh Pharmaceuticals' Bretisilocin, a Novel, Investigational Therapy for Major Depressive Disorder, Expanding Psychiatry Pipeline - PR Newswire","headline":"AbbVie to Acquire Gilgamesh Pharmaceuticals' Bretisilocin, a Novel, Investigational Therapy for Major Depressive Disorde","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxOVWNzb0ZFaE5OUjVRcFdDX1lNYzhYV3lPM2p6cXRiTEMyNmliRkVhNU5oX0plRHhhRDZ5a3ZyNUljWDBRZjdwVldLNjZVcW1hYzlTLXdkZ2lmRy1tTXRTNGNhamFxY0dWdmd1dlBhdzBsQ1g3bjRYeEFBQXNoQk12d3E4Rjlkd3BpY01Ob2xQWGRIVTg1ZW5NOHpobDlLc0t3bzF3dmlNS3ZjRnh0?oc=5","date":"2025-07-31","type":"deal","source":"Fierce Biotech","summary":"AbbVie crowns Gilgamesh its next M&A target with $1B buyout talks: report - Fierce Biotech","headline":"AbbVie crowns Gilgamesh its next M&A target with $1B buyout talks: report","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxOaXF6dGlsOUQzRm42OWhrUTN6REtxVzUzZFVlQjRhcjJWRm1GMTlnMVJPWXM3VFd1cUNVODBlVTZmWXdTU3d6MS1xZ2RZcHVPYXZhaEloNWp0YmFlVVdfSVNOc1htTWRQWlVYVWtJRmpDOFo1NWRPWnBJNjhUUmhIUFV4R2RsalNVbDZ1MnlBSlBGYzV2NjdKVWExRy10NU43bW1IRHh1amxrakZpZVp1MA?oc=5","date":"2025-07-31","type":"pipeline","source":"Fierce Pharma","summary":"AbbVie's rumored $1B pursuit of Gilgamesh could fit into its growing neuroscience portfolio - Fierce Pharma","headline":"AbbVie's rumored $1B pursuit of Gilgamesh could fit into its growing neuroscience portfolio","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}